ReviewCurrent neuropharmacology2019
Association between Serum Lipids and Antipsychotic Response in Schizophrenia.
Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients.BMC psychiatry · 2024Trial
- The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology · 2024Trial
- The associations of systemic inflammation and insulin resistance-related indicators with psychopathology and BDNF in patients with chronic schizophrenia.Frontiers in psychiatry · 2026Article
- Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia.BMC psychiatry · 2025Article
- Medication Induced Dyslipidemia in Children.Current atherosclerosis reports · 2025Review
- High-Density Lipoprotein Correlates with Cognitive Functioning in Schizophrenic Women.Brain sciences · 2024Article
- New role of platelets in schizophrenia: predicting drug response.General psychiatry · 2024Article
- Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review.Biomedicines · 2023Review
- Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients.International journal of molecular sciences · 2022Article
- Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression.Frontiers in psychiatry · 2022Article
- Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review.International journal of molecular sciences · 2021Review
- Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics.Pharmacy (Basel, Switzerland) · 2021Article
- Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia.Biomolecules · 2021Article
- A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.PloS one · 2021Article
- A Focused Review of the Metabolic Side-Effects of Clozapine.Frontiers in endocrinology · 2021Review
- Brain-Specific Oxysterols and Risk of Schizophrenia in Clinical High-Risk Subjects and Patients With Schizophrenia.Frontiers in psychiatry · 2021Article
- Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines.Frontiers in psychiatry · 2020Article
- Crosstalk between Inflammation and the BBB in Stroke.Current neuropharmacology · 2020Article
- Metabolic Problems Among People With Treatment-Resistant Schizophrenia are Not Unique to Clozapine.Journal of clinical psychopharmacologyArticle
- Brain Lipids and Lipid Droplet Dysregulation in Alzheimer's Disease and Neuropsychiatric Disorders.Complex psychiatryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic abnormalities are serious health problems in individuals with schizophrenia. Paradoxically, studies have noted an association where individuals who gained body weight or who have increased their serum lipids demonstrated a better antipsychotic response. As serum lipids serve as more specific physiological markers than body weight, the objective of this study was to review studies that examined the association between changes in serum lipids and changes in symptoms during antipsychotic treatment in individuals with schizophrenia. A Medline® literature search was performed. Fourteen studies were included and analyzed. Evidence suggests that increases in serum lipids may be associated with decreases in symptoms during antipsychotic treatment. This inverse association may be independent of confounding variables, such as weight gain, and may be most evident during treatment with clozapine. Also, according to recent randomized controlled trials, lipid-lowering agents do not appear to worsen symptoms although this needs to be further investigated in clozapine-treated patients. Future studies should investigate the association in question in a larger population and identify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.